Video

Dr. Ramakrishnan on Negative Results of the BELINDA Trial in Non-Hodgkin Lymphoma

Praveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.

Praveen Ramakrishnan, MD, assistant professor, Department of Internal Medicine, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, discusses the negative results from the phase 3 BELINDA trial (NCT03570892) and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma (NHL).

The BELINDA trial evaluated the efficacy and safety of tisagenlecleucel (tisa-cel; Kymriah) vs the current standard of care, which was salvage chemotherapy combined with autologous hematopoietic stem cell transplantation. Results showed that tisa-cel did not significantly improve outcomes in patients with relapsed/refractory NHL compared with standard treatment.

There are several potential explanations for these negative results, Ramakrishnan continues. The trial was subject to a delay in CAR T-cell product manufacturing, causing some patients scheduled to receive tisa-cel to experience prolonged wait time. In the interim, these patients were subjected to more chemotherapy, potentially skewing results. Moreover, it is possible that the highest-risk patients were selected out by investigators due to this concern.

Cross-trial comparisons are notoriously difficult to conduct, Ramakrishnan notes. It is unclear if the results from BELINDA indicate that tisa-cel is inferior to other CAR T-cell therapies such as lisocabtagene maraleucel (liso-cel; Breyanzi) and axicabtagene ciloleucel (axi-cel; Yescarta). However, both these therapies are approved for this patient population in the second-line setting, while tisa-cel is only approved for patients in the third-line setting and beyond.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma